N
SGTX

Nuveen’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Nuveen’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,740
Closed -$31K – 3580
2022
Q1 		$31K Hold
1,740
– – ﹤0.01% 3289
2021
Q4 		$57K Sell
1,740
-317
-15% -$18K ﹤0.01% 3303
2021
Q3 		$163K Buy
2,057
+183
+10% +$14.1K ﹤0.01% 3292
2021
Q2 		$261K Buy
1,874
+913
+95% +$160K ﹤0.01% 3230
2021
Q1 		$279K Buy
+961
New +$382K ﹤0.01% 3186

Other funds holding SGTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nuveen's SGTX Position: Q2 2022 in Review

Nuveen sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q2 2022, closing a stake of 1,740 shares — an estimated $31K sold.

Nuveen first reported a position in SGTX in Q1 2021 and held it in 5 quarters. The position peaked at $279K in Q1 2021. 37 funds tracked by Wall St. Rank hold SGTX as of Q2 2022.

  • Nuveen reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Nuveen sold 1,740 Sigilon Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $31K.
  • Nuveen first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
  • Nuveen's Sigilon Therapeutics, Inc. Common Stock position peaked at $279K in Q1 2021.
  • 37 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Nuveen's 13F filing for Q2 2022, filed 15 Aug 2022.